Agile Therapeutics,Inc. (NASDAQ:AGRX) Files An 8-K Other Events

Agile Therapeutics,Inc. (NASDAQ:AGRX) Files An 8-K Other Events
Item 8.01.Other Events.

Story continues below

Agile Therapeutics,Inc. (“Agile”) a women’s healthcare company, has had a poster presentation of additional results from the Phase 3 SECURE study of AG200-15 (Twirla®), an investigational, once weekly, low-dose hormonal contraceptive patch accepted at Women’s Health 2018: Translating Research into Clinical Practice being held May4ththrough May6th, 2018 in Arlington, Virginia. On Friday, May4, 2018 James Simon, MD, Clinical Professor at George Washington University will present the poster titled Wearability of a Once-Weekly Low-Dose Contraceptive Pathc in the Phase 3 SECURE Study, which includes data on the adhesion profile and wearability of AG200-15.

The SECURE clinical trial was designed to evaluate the efficacy, safety, and tolerability of AG200-15, also known as Twirla (levonorgestrel/ethinyl estradiol), in a representative population of women seeking birth control. SECURE was a 1-year, multicenter, single-arm, open-label trial in 2032 healthy women aged 18 and over, at 102 experienced investigative sites across the United States.

A copy of Agile’s poster is attached hereto as Exhibit99.1 and is hereby incorporated by reference herein.

Item 8.01.Financial Statements and Exhibits.

(d) Exhibits.


AGILE THERAPEUTICS INC Exhibit
EX-99.1 2 a18-12631_1ex99d1.htm EX-99.1 Exhibit 99.1   James A. Simona,…
To view the full exhibit click here

About Agile Therapeutics,Inc. (NASDAQ:AGRX)

Agile Therapeutics, Inc. is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.

An ad to help with our costs